Please assess the completion status of the following clinical trial:

Trial Title: Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* End-stage renal disease.~* No known contraindications for therapy with Immune Globuillin Intravenous 10%/Rituximab or C1 INH.~* Age 18-65 years at the time of screening.~* Panel Reactive Antibody \[PRA\] \> 50% demonstrated on 3 consecutive samples, Patient highly-HLA (Human Leukocyte Antigen) sensitized and a candidate for Living Donor/Deceased Donor transplantation after desensitization at Cedars Sinai Medical Center.~* At transplant, patient must have Donor Specific Antibody /Cross match + non-HLA (Human Leukocyte Antigen) identical donor.~Subject/Parent/Guardian must be able to understand and provide informed consent.~Exclusion Criteria:~* Lactating or pregnant females.~* Women of child-bearing age who are not willing or able to practice Food and Drug Administration \[FDA\]-approved forms of contraception.~* HIV-positive subjects.~* Subjects who test positive for Hepatitis B Virus infection \[positive Hepatitis B Virus surface Antigen, Hepatitis B Virus core Antigen, or Hepatitis B Virus e Antigen/DNA\] or Hepatitis C Virus infection \[positive Anti-Hepatitis C Virus (EIA) and confirmatory Hepatitis C Virus Recombinant ImmunoBlot Assay (RIBA)\].~* Subjects with active Tuberculosis.~* Subjects with selective Immunoglobulin A deficiency, those who have known anti-Immunoglobulin A antibodies, and those with a history of anaphylaxis or severe systemic responses to any part of the clinical trial material.~* Subjects who have received or for whom multiple organ transplants are planned.~* Recent recipients of any licensed or investigational live attenuated vaccine(s) within two months of the screening visit (including but not limited to any of the following:~* Adenovirus \[Adenovirus vaccine live oral type 7\] Varicella \[Varivax\] Hepatitis A \[VAQTA\] Rotavirus \[Rotashield\] Yellow fever \[Y-F-Vax\] Measles and mumps \[Measles and mumps virus vaccine live\] Measles, mumps, and rubella vaccine \[M-M-R-II\] Sabin oral polio vaccine Rabies vaccines \[IMOVAX Rabies I.D., RabAvert\])~* A significantly abnormal general serum screening lab result defined as a White Blood Cell \< .0 X 103/ml, a Hemoglobin \< 8.0 g/dL, a platelet count \< 100 X 103/ml, , an Serum Glutamic Oxaloacetic Transaminase \[SGOT\] \> 5X upper limit of normal, and an Serum Glutamic Pyruvic Transaminase \[SGPT\] \>5X upper limit of normal range.~* Individuals deemed unable to comply with the protocol.~* Subjects with active Cytomegalovirus or Epstein Barr Virus infection as defined by Cytomegalovirus-specific serology (Immunoglobulin G or Immunoglobulin M) and confirmed by quantitative Polymerase Chain Reaction with or without a compatible illness.~* Subjects with a known history of previous myocardial infarction within one year of screening.~* Subjects with a history of clinically significant thrombotic episodes, and subjects with active peripheral vascular disease.~* Use of investigational agents within 4 weeks of participation.~* Know allergy/sensitivity to C1 INH infusions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- C1 esterase inhibitor (Type: EXPERIMENTAL): 10 subjects will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
- Placebo (Type: PLACEBO_COMPARATOR): 10 subjects placebo \[normal saline\] in addition to standard of care immunosuppressive therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).